Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 19:15:100416.
doi: 10.1016/j.conctc.2019.100416. eCollection 2019 Sep.

A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan

Ryuta Asada  1 , Kenichi Yoshimura  2 , Kayo Hattori  3 , Yujiro Nonaka  1 , Hiroi Kasai  2 , Shinobu Shimizu  4
Affiliations

A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan

Ryuta Asada et al. Contemp Clin Trials Commun. .

Erratum in

Abstract

Introduction: In Japan, the PMDA conducted inspections based on GCP in the review process of the submission of NDAs or sNDAs. In this descriptive study, we examined in detail the contents of exclusion data from submitted clinical data package subjects in the results of GCP inspections in Japan for NDAs or sNDAs.

Methods: For NDAs or sNDAs approved in Japan between January 2007 and December 2017, we gathered information about the PMDA's conclusion from review reports, concerning the results of the GCP on-site inspection.

Results: For 1193 NDAs and sNDAs approved in Japan between 2007 and 2017, there were 37 cases in 33 applications of non-compliance with GCP, including 1 by the sponsor and 32 at the clinical trial site. Of the 32 applications at the clinical trial site, 9 cases were categorized as "General findings" and 28 as "Findings for individual subjects." Of the 9 "General findings" cases, problems related to the IRB were most common (44.4%), while faulty record keeping was the most common (60.7%, 95% confidence interval 42.6%-78.9%) problem in the 27 "Findings for individual subjects" cases. Violations of GCP were mostly found in 2007 and 2009, but few were found after 2013.

Conclusion: In this study, we revealed that record keeping was the most common reason for exclusion from the analysis data of subjects in the results of GCP inspections. It is necessary to be careful in maintaining medical records, especially when conducting clinical trials without using electronic medical records.

Keywords: Clinical trial; GCP; GCP inspection; GCP violation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Therapeutic categories for the 33 NDAs or sNDAs.
See this image and copyright information in PMC

References

    1. International Conference on Harmonization Harmonized Tripartite Guidelines (Step 4) Guideline for Good Clinical Practice. ICH Secretariat; Geneva: 1996.
    1. Classification and Analysis of the GCP Inspection Findings of GCP Inspections Conducted at the Request of the CHMP Inspection Reports to EMA 2000-2012. https://www.ema.europa.eu/en/documents/other/classification-analysis-goo... accessed 11 June 2019.
    1. Watanabe H., Kageyama S., Kurihara C. Actual status of GCP investigations and future perspective ─ for solution of “over quality issue”: focused on comparation of Japan, US, EU regulations. Rinsho hyoka. 2008;35 667－81. (In Japanese)
    1. Ono S., Kodama Y., Nagao T., Toyoshima S. The quality of conduct in Japanese clinical trials: deficiencies found in GCP inspections, Control. Clin. Trials. 2002;23:29–41. - PubMed
    1. Saito K., Kodama Y., Ono S., Fujimura A. Recent changes in quality in Japanese clinical trials. Ann. Pharmacother. 2004;38:151–155. - PubMed

LinkOut - more resources